Focusing on Patient Outcomes in an Era of Rising Drug Costs Tom Woller, RPh, MS, FASHP and Dalia Saleh, PharmD Focusing on Patient Outcomes in an Era of.

Slides:



Advertisements
Similar presentations
Preparing for What’s on the Prescription Drug Benefit Horizon Brenda Motheral, PhD Senior Vice President Research & Product Management.
Advertisements

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
CAHF CEO Conference May 31, Genesis HealthCare Overview “Go Private” Transaction Overview OPCO/PROPCO – REIT Transaction Questions and Answers Today’s.
Specialty Pharmacy: Today’s Prescription for a Better Tomorrow Steve Miller, MD Chief Medical Officer.
Midwest Business Group on Health National Employer Survey on Biologics/Specialty Pharmacy August 2011.
CENTRE FOR HEALTH ECONOMICS AND DEVELOPEMNT ESTIMATING ECONOMIC AND FISCAL IMPACT OF HEALTH AND NON HEALTH EXPENDITURE FROM THE NATIONAL HEALTH BILL Kenneth.
The Economic and Health Effects of Biomedical Innovation Peter R. Orszag Vice Chairman, Corporate and Investment Banking Chairman, Financial Strategy and.
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
Objective The aim was to investigate the impact of purchasing medicines jointly by the JPD for the four participating parties in the first tender on the.
Helping patients breathe more easily with affordable prescriptions Presented to Pulmonary-Allergy Advisory Committee U.S. Food and Drug Administration.
Specialty pharmaceuticals
Controlling the Bottom Line. What is specialty pharmacy? Wide variations in definitions Compounded drugs Biotech drugs Expensive drugs Workman’s Compensation.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
ACHP Live Interview High-Cost Drugs: Challenges and Opportunities June 15, 2015.
Can the Specialty Beast Be Tamed? Steven B. Miller, MD Express Scripts.
Confidential and Proprietary Information © 2014 Express Scripts Holding Company. All Rights Reserved. 1 Confidential and Proprietary Information © 2014.
Managed Care Career Path for Student Pharmacists Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Balancing revenues and costs for orphan drugs: a case study Aidan Hollis University of Calgary: Department of Economics and O’Brien Institute of Public.
PROPRIETARY & CONFIDENTIAL 1 Specialty Pharmacy Trends and AcariaHealth Specialty Pharmacy Solution AcariaHealth Presentation April 6, 2015.
Courtesy Reminders: During the webinar, you may select *7 on your phone to speak, and use *6 to mute. Please refrain from placing the phone on HOLD during.
Courtesy Reminders: During the webinar, you may select *7 on your phone to speak, and use *6 to mute. Please refrain from placing the phone on HOLD during.
PBS Data Flow Prescriptions are written by approved prescribers Drugs are supplied to patients by approved suppliers S90 pharmacies and Friendly societies.
CLER Pathways II January 28, 2016 PARTNERS IN MEDICAL EDUCATION, INC. Presented by: Tori Hanlon, MS, CHCP GME Consultant.
Care Transitions for Medication Safety in the Community
Effective Prescription Safety Net Programs in Action
EVP, Chief Medical Officer CEO Advocate Physician Partners
Managed Care Models: The Benefit vs. Cost Balance
Enhancing the Medication Reconciliation Process during Transitions of Care Utilizing Student Pharmacists Marco DelBove, Pharm.D. Memorial Hospital of Rhode.
HEALTH CARE SPENDING, COST AND WASTE
of Patients with Acute Myocardial Infarction (AMI)
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Drug Management Updates
Industry Section Presentation: Health System Pharmacy 101- How Vendors Can Add Value & Partner Sidney P Phillips PharmD, RPh, MBA 11/7/16.
Clinical Leadership Decision Process
A Conversation on Population Health & Wellbeing
The Basics of Pharmacy Benefit Management (PBM)
Value of Pharmaceuticals in Managed Care Pharmacy
Bending the Cost Curve A Case for Integration.
National Trends in Per Capita Pharmaceutical Spending, 1980–2015
Specialty Pharmacy Management
College of Public Health and Human Sciences
An Increasing Demand for Prescription Drugs Drives Profitability
Value of Pharmaceuticals in Managed Care Pharmacy
Value of Pharmaceuticals in Managed Care Pharmacy
Sergio Bautista-Arredondo National Institute of Public Health Mexico
Presented by: Mark J. Higley V-P, Regulatory Affairs VGM Group, Inc.
Most leaders support competitive bidding for medical equipment prices and negotiation of drug prices by Medicare. “Medicare is the largest payer for health.
Finance Manager’s Report
The Complexity of Pharmacy Benefits
PGY1/PGY2 Health System Pharmacy Administration Residency Program
Market for Primary Care
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
2019 Medicare Part D Rule Opioid-related Provisions
Financial Industry Group 4/20/2011
Pharmacy – Fully Insured versus Self Funding
State of the pharmacy market
The Rx for Rx Savings Breaking the Status Quo!
Ryan Czado, PharmD, MBA Director of Pharmacy Solutions
The Science Behind Falls Management
Finance Committee Review
How much is health spending expected to grow?
ACEC Membership Survey and Association Trends
Why Physicians Leaders Need to Understand Cost Management
Value of Pharmaceuticals in Managed Care Pharmacy
Welcome! Please keep phones muted while not speaking to eliminate background noise. If you are using your computer for audio, click the microphone button.
Diabetic Retinopathy Clinical Research Network
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

Focusing on Patient Outcomes in an Era of Rising Drug Costs Tom Woller, RPh, MS, FASHP and Dalia Saleh, PharmD Focusing on Patient Outcomes in an Era of Rising Drug Costs    Tom Woller, RPh, MS, FASHP and Dalia Saleh, PharmD    June 9 th from 12:00pm - 1:00 pm Courtesy Reminders: During the webinar, you may select *7 on your phone to speak, and use *6 to mute. Please refrain from placing the phone on HOLD during the presentation.

Today’s Presenters Tom Woller, RPh, MS, FASHP Senior Vice President Pharmacy Services Aurora Health Care Dalia Saleh, PharmD PGY2 Health-System Pharmacy Administration Resident Aurora Health Care

3 Today’s Webinar Agenda I.Background on Today’s Drug Market II.Understanding the Nuances of Cost and Outcomes III.What Should Pharmacy Directors Budget? IV.What Should Hospital Leaders Expect from Their Pharmacy Directors? V.Q&A

Health Care Costs Are Rising

Today’s Drug Market

Why does drug spend increase in the hospital?  Utilization changes  Business growth  Unit price increases

Unit Price Increases?  Ingredient cost  Market exclusivity – Line availability – Pharma acquisitions – Old drugs now requiring FDA approval

Market Exclusivity  Line availability  Market forces  Pay for delay Nelson R. Medscape Medical News. April 2015.

Market Exclusivity Rockoff JD, Silverman E. Wall Street Journal. April 2015.

How does this impact hospitals?  Example: Aurora Health Care ISUPRELNITROPRESS UnitsSpendUnitsSpend 2013 Baseline usage Baseline spend $66,000 Baseline usage Baseline spend $185, % of baseline 2706% of baseline $1,796,000 67% of baseline 797% of baseline $944,000

Market Exclusivity “Cleveland Clinic says the price hikes for the two Valeant drugs is unexpectedly adding $8.6 million, or 7%, to this year’s budget of roughly $122 million for medicines administered at its hospitals.” Rockoff JD, Silverman E. Wall Street Journal. April 2015.

Market Exclusivity  Pharma consolidation example  Actavis acquired Allergan, Inc  Actavis renamed itself Allergan, Plc  Allergan, Plc acquired Kythera Biopharmaceuticals  Allergan, Plc sold “legacy Actavis” generics to Teva  Pfizer acquired Hospira  Pfizer + Allergan announced

Market Exclusivity  FDA examining old drugs that don’t have FDA- approval  Vasopressin example – Discontinuations by multiple manufacturers – Vasostrict® introduced (only FDA-approved option) ASHP Drug Shortages. 13 May 2015.

How does this impact hospitals?  Example: Aurora Health Care  Vasopressin in every code cart Q1 of 2014Box of Vasopressin$90 Q1 of 2015 Box of Vasopressin$900 Box of Vasostrict®$1200 Q1 of 2016Box of Vasostrict®$2600

Why? Because They Can.

Value – Balancing Outcomes & Cost  Value depends on your viewpoint  Evaluation of alternatives  Consider: – Quantity & quality of life – Return to work – Patient wishes – Length of strength – Readmission risk

Outcomes vs Cost  Example: Ipilimumab (Yervoy®) for Melanoma – Increase in life expectancy: 1.88 years (mean) – Estimated incremental cost: $146,700  Quality of Life? – Increase in “quality adjusted life years”: 1.14 QALYs – Estimated incremental cost-effectiveness ratio of $128,660 per QALY gained Barzy V, et al. J Med Econ. Oct 2012.

Outcomes vs Cost  Institute for Clinical and Economic Review (ICER) – “A price tag on hope?” – Comparative-effectiveness analyses Goozner M. Modern Healthcare. May 2016.

Specialty Drugs  Projected increase of 17% each year  2018: Specialty will be 50% of all drug spend  2020: Specialty will be 9.1% of all health spend Express Scripts. Drug Trend Report Pew Charitable Trusts Fact Sheet. Nov 2015.

PWC Health Research Institute Drug costs are the fastest growing health care expenditure $87 billion $192 billion $402 billion $402 billion National Specialty Drug Spending

Example – Hepatitis C  Sovaldi – $1000 per tablet  Harvoni – $1125 per tablet Express Scripts Drug Trend Report

Harvoni therapyDAA-based triple therapy >95% cure rate<75% cure rate More tolerableLess tolerable Once daily pillMultiple doses per day $94,000 (12 wks)TVR - $55,000 (12 wks) IFN/RBV - $20,000 (48 wks) Liver transplant - $580,000 Example – Hepatitis C Bichoupan K, et al. Hepatology. August 2014.

What is Our Priority? Patient Care

Example – Vaccines Usage increase  Spend increase This is not a bad thing

To Pharmacy Directors  Budget preparation – Projecting expenditure – Networking, socializing – Increasing your understanding  Integrate quality measures  Monitor trends  Understand net revenue  Have plans for improving cost and quality (value)

What Hospital Leaders Should Expect From Their Pharmacy Directors  Expect the Pharmacy Director to prepare projections and budget (not finance!)  Expect comprehensive variance reporting  Expect communication across disciplines  Don’t expect them to make up the differences – Drives bad behavior  Expect them to talk about both costs and quality (value)

27 Questions?

Please complete the brief post-webinar survey. Thank you for attending today’s webinar. Tom Woller, Dalia Saleh,